LAS VEGAS, Oct. 16, 2018 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and media firm focused on the developing cannabis market, is pleased to announce that its new Board Member and Chief Science Officer, Dr. Cindy Orser, has been asked to speak on Cannabinoids and Terpenes at the 2018 MJBizCon Science Symposium in Las Vegas this November.
Dr. Orser has been a leader in bringing transparency to the cannabis consumer by distilling down analytical findings from chemical profiling of thousands of cannabis samples at Digipath Labs in Las Vegas, NV where she serves as it's Chief Science Officer. One of her primary focuses has been on exposing the unregulated basis for strain naming. Dr. Orser's other focus has been her analytical research on cannabis terpenoid profiles and keen interest in assigning further physiological meaning to individual terpenoids.
Dr. Orser commented, "I was given the opportunity two years ago to deliver the opening "Cannabis Science" keynote address at the MJBizCon Science Symposium and learned so much researching, organizing and delivering my talk that I was eager to return this year."
Todd Denkin, President and COO of Digipath Labs said, "We encourage anyone interested in learning what's new in cannabis science to attend Dr. Orser's presentation on November 14th in Las Vegas."
About MJBizCon Science Symposium
The Science Symposium is designed as a primer for cannabis entrepreneurs who are seeking a greater familiarity with the plant and its applications that will lead to the development of best practices for producing consumer-friendly marijuana products. This full-day program will address topics ranging from research to final-product testing and includes a networking luncheon and question-and-answer session with industry experts. https://mjbizconference.com/vegas/science-symposium/
About Digipath, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.